NASHVILLE, Tenn. / Apr 25, 2024 / Business Wire / Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that it will release its financial results for the first quarter ended March 31, 2024, on Monday, May 13, 2024, after the market close. The Company will also post its first quarter Letter to Stockholders to the “Investors” section of its website, harrow.com. Harrow will host a conference call and live webcast at 8:00 a.m. Eastern Time on Tuesday, May 14, 2024, to discuss the results and provide a business update.
| Conference Call Details: |
| |
Date: | Tuesday, May 14, 2024 | |
Time: | 8:00 a.m. Eastern time | |
Participant Dial-in: | 1-833-953-2434 (U.S.) | |
Replay Dial-in (Passcode 3093849): (telephonic replay through May 21, 2024) | 1-877-344-7529 (U.S.) | |
Webcast: (online replay through May 14, 2025) |
About Harrow
Harrow, Inc. (Nasdaq: HROW) is a leading eyecare pharmaceutical company engaged in the discovery, development, and commercialization of innovative ophthalmic pharmaceutical products for the North American market. Harrow helps eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of patients each year. For more information about Harrow, please visit harrow.com.
| Last Trade: | US$41.43 |
| Daily Change: | 0.13 0.31 |
| Daily Volume: | 258,204 |
| Market Cap: | US$1.530B |
November 24, 2025 November 10, 2025 October 06, 2025 September 26, 2025 September 08, 2025 | |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
